Korro Bio, Inc. (KRRO) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc., a Delaware corporation and emerging growth company, on June 21, 2024. The report covers events occurring on June 17, 2024. The company is headquartered in Cambridge, MA, and its common stock trades on The Nasdaq Capital Market under the symbol KRRO.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
Under Item 5.02, the company reported the departure of a key officer:
- Resignation: Steve Colletti, Ph.D., notified the company of his intent to resign as Chief Scientific Officer.
- Effective Date: The resignation is effective August 2, 2024.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the executive departure.
Key Facts for Investor Verification
- Verify the timeline for the appointment of a new Chief Scientific Officer to replace Dr. Colletti.
- Confirm whether Dr. Colletti's departure impacts ongoing clinical trials or research programs.
- Review subsequent filings for any changes to the company's strategic direction following this leadership change.